Prostate Cancer risk factors

This page presents the risk factors for prostate cancer, including age, family history, ethnicity, diet, alcohol and smoking, bodyweight and physical activity, medications and medical procedures and medications, endogenous hormones and diabetes mellitus.

No modifiable risk factor for prostate cancer has been identified and therefore, at present, there is insufficient evidence on which to base a prevention strategy. The established risk factors are age, family history and ethnicity.

Many other factors have been studied but the evidence is inconclusive. One reason for this may be that different factors are involved in the development and promotion of aggressive disease compared to non-aggressive disease, making epidemiological studies of prostate cancer particularly complex. 1

Interpretation of prostate cancer risk factors has been further complicated in the PSA era, when identification of many prostate cancers is dependent on a threshold PSA level, which in turn is affected by other exposures such as body mass. This blurs the distinction between ‘cases’ and ‘controls’ leading to the possibility of PSA-detection bias. 2

 

Age and prostate cancer risk

The strongest known risk factor for prostate cancer is age, with very low risk in men under 50 and rising risk with increasing age thereafter ( Figure 4.1). The older the man, the higher the risk and this ties in with post-mortem results where approximately 80% of men by age 80 were shown to have cancer cells in their prostate. 3

New cases and rates of prostate cancer diagnosed in the UK in 2005

Download this chart (38.5kb)

 

Family history and prostate cancer risk

A family history of prostate cancer is one of the strongest known risk factors for this disease. It has been estimated that 5-10% of all prostate cancer cases and 30-40% of early-onset cases (men diagnosed <55 years) are caused by inherited susceptibility genes. 4, 5

Risk increases two to three times for men with a first-degree relative diagnosed with prostate cancer. 6 If the relative is <60 years old at diagnosis or more than one relative is affected (at any age), the individual’s risk is four times the average. These factors combine so that if more than one relative is affected by early-onset prostate cancer, the risk is increased by seven-fold. 5

A strong family history of breast cancer may also affect a man’s risk of prostate cancer, particularly if the family members were diagnosed under the age of 60. In particular, germline mutations in the breast cancer susceptibility genes, BRCA1 and BRCA2, can predispose men to prostate cancer (for more detail see  Molecular biology and genetics)

Recently, genome-wide association studies have identified several genetic variants that each slightly increase prostate cancer risk. 7-11 However, because such genetic variants are common in the population, they may contribute to a significant proportion of all prostate cancer cases. Current research in this area is likely to identify further variants in the next few years. Genetic profiling is being used to inform prostate screening and treatment.

 

Ethnicity and prostate cancer risk

Variation in incidence rates around the world and within countries, suggests that risk is affected by ethnicity. In the UK, black Caribbean and black African men have approximately two to three times the risk of being diagnosed or dying from prostate cancer than white men, while Asian men generally 12 have a lower risk than the national average. 12-14

These results echo those from the USA where black American men have higher rates than white American men and indeed the highest recorded in the world, while Asian American men have much lower rates. However, migration studies show an increase in risk as men move from low-risk to higher-risk countries, suggesting that lifestyle factors play an important role. For example, South Asian men living in the UK have a higher risk of prostate cancer than men living in South Asia. 15

 

Diet and prostate cancer risk

Diet has been extensively researched because of the large variation in prostate cancer incidence between different cultures and their traditional diets around the world, particularly the Asian versus ‘western’ diet. A variety of factors have been looked at but much of the research is at present inconclusive. A recent review of the evidence concluded that foods containing lycopenes and selenium probably have a protective effect while diets high in calcium may increase risk. 16

Lycopene

Lycopene, found principally in tomatoes and tomato-based products, may reduce the risk of prostate cancer. Cooked and processed tomatoes, such as tomato sauce, are a better source of lycopene than fresh tomatoes. A meta-analysis of 21 studies published from 1966-2003, showed that men with the highest intake of cooked tomato products had a 20% reduced risk of prostate cancer compared to men with the lowest intake. 17

Since then, three studies including the European Investigation into Cancer and Nutrition (EPIC) study 18-20 have shown a significant protective effect with higher intake of lycopene, although three other studies showed no association. 21-23

Selenium

Several studies have shown a protective association for selenium, reporting a 30-80% risk reduction for prostate cancer. 24-26 However, at least three studies showed no association. 27-30 In addition,the Selenium and Vitamin E Cancer Prevention Trial (SELECT) has not shown a reduction in prostate cancer risk for men receiving selenium and vitamin E supplements. 30

Calcium and dairy products

Some cohort studies have shown a raised risk of prostate cancer for men with high intakes of calcium from diet and/or supplementation 31-34 but others have not. 35-37

Dairy products, as a source of calcium, have been extensively studied in relation to prostate cancer. Several cohort studies show a small significant increase in risk but findings differ by whether it affects advanced or localised tumours. 34-39

The EPIC study showed overall a 32% increased risk for 35g/day higher intake of dairy protein and a 7% risk increase for an 0.3g/day intake of dairy calcium. Protein and calcium from non-dairy sources were not associated with risk. 40

Fat and meat

Extensive research into fat intake has been inconclusive. One difficulty is measurement of the different types of fat intake including saturated and unsaturated fat as well as fatty acids such as ?-linolenic acid , an omega-3 polyunsaturated fatty acid. A recent large multi-ethnic cohort study found no increase in prostate cancer for any source of fat and therefore did not support earlier studies that showed a raised risk. 41

Further studies are needed, especially as ?-linolenic acid may protect against cardiovascular disease and therefore its role for prostate cancer needs to be clarified. 42 Meat intake, particularly red and processed meat , has been studied in relation to prostate cancer but findings are inconsistent.

Fruit and vegetables

Some studies 43-45 have shown a lower risk of prostate cancer for men consuming high quantities of cruciferous vegetables but this was not confirmed in the EPIC study which studied 130,000 men and found no association between total fruit and vegetable intake or cruciferous vegetables and risk of prostate cancer. 46

Vitamin E, green tea and soy

The Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study in smokers showed a 32% reduction in risk of prostate cancer in men receiving daily alpha-tocopherol (the major form of vitamin E in supplements). 47 Other studies have shown little or no association. Further research is underway to clarify the equivocal results, in the SELECT trial. 30

Green tea has been studied due to its regular consumption by Japanese and Chinese men whose prostate cancer risk is low. Green tea contains high level of polyphenols which have anti-oxidant effects. 48 One cohort 49 and one case-control study 50 showed a reduced risk of prostate cancer with green tea consumption and a dose-response relationship with the quantity drunk, although a third study found no effect. 51 More research into the possible chemopreventive properties of green tea is needed.

East Asian diets have higher soy content than western diets, for example, with the consumption of tofu, soymilk and miso. As the incidence of prostate cancer is lower in these countries, soy and isoflavones have been studied to see if they are protective factors but findings are inconsistent.

 

Alcohol and smoking

Two meta-analyses of alcohol consumption and prostate cancer have been carried out. The largest study found no association 52 whilst the other showed only small risk increases, although dose-related, of 5%, 9% and 19% with consumption of 25, 50 and 100 grams per day . 53 Findings since these meta-analyses have been inconsistent.

A higher risk of fatal prostate cancer in smokers compared to non-smokers has been shown in some studies. 54, 55 However, no clear trends were shown with number of cigarettes smoked per day or between current, ex- and never-smokers. Two large studies concluded that smoking is not likely to be linked to either the incidence or mortality of prostate cancer. 56, 57

 

Bodyweight and physical activity

Obesity is a major health problem in the UK and has been linked to several major cancers. 58, 59 However, it is not yet proven to be an important risk factor for prostate cancer.

A recent meta-analysis reported a small borderline significant increase in prostate cancer risk with increasing body mass index (BMI). 60 Some cohort studies indicate that obese men are at greater risk of dying from prostate cancer 61-63 while others have reported a reduced risk of localised prostate cancer in men with a high BMI. 64, 65 Although the evidence is far from clear for prostate cancer, general health advice would be for men to maintain a healthy BMI.

Physical inactivity 66 has been linked to several serious diseases such as diabetes and heart disease as well as some cancers, particularly colon cancer, but there is no strong link with prostate cancer. 59

medical procedures

Endogenous hormones

It has long been suggested that high circulating levels of sex hormones are associated with an increased risk of prostate cancer as most prostate cancers respond favourably to androgen-deprivation and castrated men do not develop prostate cancer. However, the most recent worldwide re-analysis of 18 prospective studies, including the EPIC study, has shown no association between endogenous sex hormones and risk of prostate cancer overall.

Insulin-like growth factor (IGF-1) is an easily measurable protein that is involved in normal cell proliferation and death. Both a recent meta-analysis and a large Swedish study found that higher concentrations of IGF-1 were associated with an increased risk of prostate cancer with a clear dose-response relationship.

However, other studies including EPIC have shown no association. IGF-1 levels may mediate the effects of many environmental exposures as its levels are regulated by other cancer risk factors such as bodyweight, diet and physical exercise. The relationship between several components of the IGF system and prostate cancer is undergoing further investigation.

infections and prostate cancer risk" name="Medications

Diabetes mellitus

The risk of prostate cancer was significantly lower, by 16% in the most recent meta-analysis, among men with diabetes mellitus than among those without this condition but why this is so is not clear. 84, 85 A number of possible mechanisms are discussed in the latest meta-analysis 85 and recent research suggests that there may be a genetic link between diabetes and prostate cancer. 86

Browse related content

References for prostate cancer risk factors

  1.  Giovannucci, E., et al., Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer, 2007. 121(7): p. 1571-8
  2.  Platz, E.A., A.M. De Marzo, and E. Giovannucci, Prostate cancer association studies: pitfalls and solutions to cancer misclassification in the PSA era. J Cell Biochem, 2004. 91(3): p. 553-71
  3.  Sakr, W.A., et al., Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol, 1996. 30(2): p. 138-44
  4.  Bratt, O., Hereditary prostate cancer: clinical aspects. J Urol, 2002. 168(3): p. 906-13
  5.  Carter, B., et al.,   Proc Natl Acad Sci, 1992. 89: p. 3367-71
  6.  Johns, L.E. and R.S. Houlston, A systematic review and meta-analysis of familial prostate cancer risk. BJU Int, 2003. 91(9): p. 789-94
  7.  Eeles, R.A., et al., Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet, 2008
  8.  Amundadottir, L.T., et al., A common variant associated with prostate cancer in European and African populations. Nat Genet, 2006. 38(6): p. 652
  9.  Thomas, G., et al., Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet, 2008. 40(3): p. 310-5
  10.  Zheng, S.L., et al., Association Between Two Unlinked Loci at 8q24 and Prostate Cancer Risk Among European Americans. J. Natl. Cancer Inst., 2007. 99(20): p. 1525-1533
  11.  Haiman, C.A., et al., A common genetic risk factor for colorectal and prostate cancer. Nat Genet, 2007. 39(8): p. 954
  12.  Jack, R.H., E.A. Davies, and H. Moller, Testis and prostate cancer incidence in ethnic groups in South East England. Int J Androl, 2007. 30(4): p. 215-20; discussion 220-1
  13.  Ben-Shlomo, Y., et al., The risk of prostate cancer amongst black men in the United Kingdom: the PROCESS cohort study. Eur Urol, 2008. 53(1): p. 99-105
  14.  Wild, S.H., et al., Mortality from all cancers and lung, colorectal, breast and prostate cancer by country of birth in England and Wales, 2001-2003. Br J Cancer, 2006. 94(7): p. 1079-85
  15.  Winter, H., et al., Cancer incidence in the south Asian population of England (1990-92). Br J Cancer, 1999. 79(3-4): p. 645-54
  16.  World Cancer Research Fund and American Institute for Cancer Research, Food, nutrition, physical activity and the prevention of cancer: A global perspective. 2007, Washington: American Institute for Cancer Research.
  17.  Etminan, M., B. Takkouche, and F. Caamano-Isorna, The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. Cancer Epidemiol Biomarkers Prev, 2004. 13(3): p. 340-5
  18.  Zhang, J., et al., Plasma carotenoids and prostate cancer: a population-based case-control study in Arkansas. Nutr Cancer, 2007. 59(1): p. 46-53
  19.  Wu, K., et al., Plasma and dietary carotenoids, and the risk of prostate cancer: a nested case-control study. Cancer Epidemiol Biomarkers Prev, 2004. 13(2): p. 260-9
  20.  Key, T.J., et al., Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr, 2007. 86(3): p. 672-681
  21.  Peters, U., et al., Serum lycopene, other carotenoids, and prostate cancer risk: a nested case-control study in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev, 2007. 16(5): p. 962-8
  22.  Kirsh, V.A., et al., A prospective study of lycopene and tomato product intake and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev, 2006. 15(1): p. 92-8
  23.  Bosetti, C., et al., Retinol, carotenoids and the risk of prostate cancer: a case-control study from Italy. Int J Cancer, 2004. 112(4): p. 689-92
  24.  van den Brandt, P.A., Zeegers, M. P. A., Bode, P. and Goldbohm, R. A., Toenail Selenium Levels and the Subsequent Risk of Prostate Cancer: A Prospective Cohort Study. Cancer Epidemiol Biomarkers Prev, 2003. 12: p. 866-871
  25.  Yoshizawa, K., et al., Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst, 1998. 90(16): p. 1219-24
  26.  Brooks, J.D., et al., Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol, 2001. 166(6): p. 2034-8
  27.  Vogt, T.M., et al., Serum selenium and risk of prostate cancer in U.S. blacks and whites. Int J Cancer, 2003. 103(5): p. 664-70
  28.  Hartman, T.J., et al., The association between baseline vitamin E, selenium, and prostate cancer in the alpha-tocopherol, beta-carotene cancer prevention study. Cancer Epidemiol Biomarkers Prev, 1998. 7(4): p. 335-40
  29.  Goodman, G.E., et al., Predictors of serum selenium in cigarette smokers and the lack of association with lung and prostate cancer risk. Cancer Epidemiol Biomarkers Prev, 2001. 10(10): p. 1069-76
  30.  Selenium and Vitamin E Cancer Prevention Trial.
  31.  Giovannucci, E., et al., A prospective study of calcium intake and incident and fatal prostate cancer. Cancer Epidemiol Biomarkers Prev, 2006. 15(2): p. 203-10
  32.  Mitrou, P.N., et al., A prospective study of dietary calcium, dairy products and prostate cancer risk (Finland). Int J Cancer, 2007. 120(11): p. 2466-73
  33.  Rodriguez, C., et al., Calcium, Dairy Products, and Risk of Prostate Cancer in a Prospective Cohort of United States Men. Cancer Epidemiol Biomarkers Prev, 2003. 12(7): p. 597-603
  34.  Ahn, J., et al., Dairy products, calcium intake, and risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev, 2007. 16(12): p. 2623-30
  35.  Park, Y., et al., Calcium, dairy foods, and risk of incident and fatal prostate cancer: the NIH-AARP Diet and Health Study. Am J Epidemiol, 2007. 166(11): p. 1270-9
  36.  Park, S.Y., et al., Calcium, vitamin D, and dairy product intake and prostate cancer risk: the Multiethnic Cohort Study. Am J Epidemiol, 2007. 166(11): p. 1259-69
  37.  Rohrmann, S., et al., Meat and dairy consumption and subsequent risk of prostate cancer in a US cohort study. Cancer Causes Control, 2007. 18(1): p. 41-50
  38.  Tseng, M., et al., Dairy, calcium, and vitamin D intakes and prostate cancer risk in the National Health and Nutrition Examination Epidemiologic Follow-up Study cohort. Am J Clin Nutr, 2005. 81(5): p. 1147-54
  39.  Kurahashi, N., et al.,  Dairy Product, Saturated Fatty Acid, and Calcium Intake and Prostate Cancer in a Prospective Cohort of Japanese Men. Cancer Epidemiol Biomarkers Prev, 2008. 17(4): p. 930-937
  40.  Allen, N.E., et al., Animal foods, protein, calcium and prostate cancer risk: the European Prospective Investigation into Cancer and Nutrition. Br J Cancer, 2008
  41.  Park, S.Y., et al., Fat and meat intake and prostate cancer risk: the multiethnic cohort study. Int J Cancer, 2007. 121(6): p. 1339-45
  42.  Platz, E.A. and Giovannucci E, Prostate cancer, in Cancer Epidemiology and Prevention, F.J. Schottenfeld D, Editor. 2006.
  43.  Cohen, J.H., A.R. Kristal, and J.L. Stanford, Fruit and vegetable intakes and prostate cancer risk. J Natl Cancer Inst, 2000. 92(1): p. 61-8
  44.  Kirsh, V.A., et al., Prospective study of fruit and vegetable intake and risk of prostate cancer. J Natl Cancer Inst, 2007. 99(15): p. 1200-9
  45.  Kolonel, L.N., et al., Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. Cancer Epidemiol Biomarkers Prev, 2000. 9(8): p. 795-804
  46.  Key, T.J., et al., Fruits and vegetables and prostate cancer: No association among 1,104 cases in a prospective study of 130,544 men in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer, 2004. 109(1): p. 119-24
  47.  Heinonen, O.P., et al., Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst, 1998. 90(6): p. 440-6
  48.  Syed, D.N., et al., Chemoprevention of Prostate Cancer through Dietary Agents: Progress and Promise. Cancer Epidemiol Biomarkers Prev, 2007. 16(11): p. 2193-2203
  49. 4
  50.  Kurahashi, N., et al., Green tea consumption and prostate cancer risk in Japanese men: a prospective study. Am J Epidemiol, 2008. 167(1): p. 71-7
  51.  Jian, L., et al., Protective effect of green tea against prostate cancer: a case-control study in southeast China. Int J Cancer, 2004. 108(1): p. 130-5
  52.  Kikuchi, N., et al., No association between green tea and prostate cancer risk in Japanese men: the Ohsaki Cohort Study. Br J Cancer, 2006. 95(3): p. 371-3
  53.  Bagnardi, V., et al., A meta-analysis of alcohol drinking and cancer risk. Br J Cancer, 2001. 85(11): p. 1700-5
  54.  Dennis, L.K., Meta-analysis for combining relative risks of alcohol consumption and prostate cancer. Prostate, 2000. 42(1): p. 56-66
  55.  Gong, Z., et al., Cigarette smoking and prostate cancer-specific mortality following diagnosis in middle-aged men. Cancer Causes Control, 2008. 19(1): p. 25-31
  56.  Rohrmann, S., et al., Smoking and risk of fatal prostate cancer in a prospective U.S. study. Urology, 2007. 69(4): p. 721-5
  57.  Adami, H.O., et al., A prospective study of smoking and risk of prostate cancer. Int J Cancer, 1996. 67(6): p. 764-8
  58.  Doll, R., et al., Mortality from cancer in relation to smoking: 50 years observations on British doctors. Br J Cancer, 2005. 92(3): p. 426-9
  59.  Bergstrom, A., et al., Overweight as an avoidable cause of cancer in Europe. Int J Cancer, 2001. 91: p. 421-430
  60.  Cancer Research UK, Lifestlye and Cancer Accessed 2008
  61.  Renehan, A.G., et al., Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet, 2008. 371(9612): p. 569-78
  62.  Rodriguez, C., et al., Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev, 2001. 10(4): p. 345-53
  63.  Andersson, S.O., et al., Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst, 1997. 89(5): p. 385-9
  64.  Calle, E.E., et al., Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med, 2003. 348(17): p. 1625-38
  65.  Wright, M.E., et al., Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer, 2007. 109(4): p. 675-84
  66.  Gong, Z., et al., Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev, 2006. 15(10): p. 1977-83
  67.  Craig R and Mindell J, Health Survey For England, Latest Trends. 2008.
  68.  Mahmud, S., E. Franco, and A. Aprikian, Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer, 2004. 90(1): p. 93-99
  69.  Browning, D.R. and R.M. Martin, Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer, 2007. 120(4): p. 833-43
  70.  Platz, E.A., Epidemiologic Musing on Statin Drugs in the Prevention of Advanced Prostate Cancer. Cancer Epidemiol Biomarkers Prev, 2007. 16(11): p. 2175-2180
  71.  Dennis, L.K., D.V. Dawson, and M.I. Resnick, Vasectomy and the risk of prostate cancer: a meta-analysis examining vasectomy status, age at vasectomy, and time since vasectomy. Prostate Cancer Prostatic Dis, 2002. 5(3): p. 193-203
  72.  Rohrmann, S., et al., Association of vasectomy and prostate cancer among men in a Maryland cohort. Cancer Causes Control, 2005. 16(10): p. 1189-94
  73.  Taylor, M.L., A.G. Mainous, 3rd, and B.J. Wells,  Prostate cancer and sexually transmitted diseases: a meta-analysis. Fam Med, 2005. 37(7): p. 506-12
  74.  Sutcliffe, S., et al., Gonorrhea, syphilis, clinical prostatitis, and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev, 2006. 15(11): p. 2160-6
  75.  Wu, C.P. and F.L. Gu, The prostate in eunuchs. Prog Clin Biol Res, 1991. 370: p. 249-55
  76.  Travis, R.C., et al., Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer, 2007. 121(6): p. 1331-8
  77.  Roddam, A.W., et al., Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst, 2008. 100(3): p. 170-83
  78.  Renehan, A., Zwahlen, M, Minder, C, O'Dwyer, S T, Shalet, S M and Egger, M, Insulin-like growth factor (IGF)-1, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet, 2004. 363: p. 1346-53
  79.  Stattin, P. et al High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. J Clin Oncol, 2004. 22(15): p. 3104-12
  80.  Woodson, K., et al., Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res, 2003. 63(14): p. 3991-4
  81.  Meyer, F., et al., A prospective study of the insulin-like growth factor axis in relation with prostate cancer in the SU.VI.MAX trial. Cancer Epidemiol Biomarkers Prev, 2005. 14(9): p. 2269-72
  82.  Allen, N.E., et al., Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev, 2007. 16(6): p. 1121-7
  83.  Oliver, S.E., et al., Screen-detected prostate cancer and the insulin-like growth factor axis: Results of a population-based case-control study. Int J Cancer, 2004. 108(6): p. 887-92
  84.  Martin RM et al, The IGF system in prostate cancer aetiology and prognosis: a large population-based cohort study., Cancer Research UK Project grant (C18281/A7062). Jan 2007 to Dec 2009.
  85.  Bonovas, S., K. Filioussi, and A. Tsantes, Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia, 2004. 47(6): p. 1071-8
  86.  Kasper, J.S. and E. Giovannucci, A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev, 2006. 15(11): p. 2056-62
  87.  Gudmundsson, J et al Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes Nat Genet, 2007. 39(8): p. 977-83